Stockscreener 앱 받기
64.10
1.55%
-1.01
시간 외 거래:
63.76
-0.34
-0.53%
전일 마감가:
$65.11
열려 있는:
$65.54
하루 거래량:
1.53M
Relative Volume:
0.78
시가총액:
$7.50B
수익:
$947.36M
순이익/손실:
$392.47M
주가수익비율:
21.23
EPS:
3.02
순현금흐름:
$392.71M
1주 성능:
-7.07%
1개월 성능:
-15.44%
6개월 성능:
+11.09%
1년 성능:
+22.96%
1일 변동 폭
$63.78
$65.59
1주일 범위
$63.78
$68.83
52주 변동 폭
$42.01
$79.50
Halozyme Therapeutics Inc Stock (HALO) Company Profile
명칭
Halozyme Therapeutics Inc
전화
(858) 794-8889
주소
12390 EL CAMINO REAL, SAN DIEGO, CA
HALO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HALO
Halozyme Therapeutics Inc
|
64.10 | 7.62B | 947.36M | 392.47M | 392.71M | 3.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-06 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-10 | 재개 | Goldman | Neutral |
| 2025-05-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | 다운그레이드 | Leerink Partners | Market Perform → Underperform |
| 2024-10-07 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-09-19 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-06-07 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2024-02-29 | 개시 | TD Cowen | Outperform |
| 2023-07-24 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-07-24 | 개시 | H.C. Wainwright | Buy |
| 2023-05-10 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | 재개 | Berenberg | Buy |
| 2023-03-16 | 다운그레이드 | SVB Securities | Outperform → Market Perform |
| 2022-12-21 | 재개 | Morgan Stanley | Overweight |
| 2022-11-28 | 개시 | Wells Fargo | Overweight |
| 2022-09-09 | 개시 | Morgan Stanley | Overweight |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2021-06-14 | 개시 | Evercore ISI | Outperform |
| 2021-05-17 | 개시 | SVB Leerink | Outperform |
| 2021-05-11 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-01-21 | 재확인 | The Benchmark Company | Buy |
| 2020-12-17 | 개시 | Berenberg | Buy |
| 2020-09-14 | 재개 | JP Morgan | Overweight |
| 2020-07-01 | 개시 | The Benchmark Company | Buy |
| 2020-02-05 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2020-01-09 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2020-01-08 | 개시 | Goldman | Buy |
| 2019-11-05 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2018-10-19 | 재개 | Piper Jaffray | Neutral |
| 2018-05-11 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2018-01-24 | 개시 | Goldman | Neutral |
| 2017-10-16 | 재확인 | Piper Jaffray | Overweight |
| 2017-01-06 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2016-11-03 | 개시 | Deutsche Bank | Buy |
| 2015-12-04 | 개시 | Wells Fargo | Outperform |
| 2015-11-18 | 개시 | Citigroup | Buy |
| 2015-09-22 | 개시 | Barclays | Overweight |
| 2015-06-22 | 재확인 | JP Morgan | Overweight |
| 2015-03-03 | 재확인 | UBS | Buy |
| 2015-02-18 | 재확인 | MLV & Co | Buy |
| 2015-01-08 | 재확인 | MLV & Co | Buy |
모두보기
Halozyme Therapeutics Inc 주식(HALO)의 최신 뉴스
Strong And Rising: Halozyme Therapeutics Stock May Have More Upside - Forbes
What technical models suggest about Halozyme Therapeutics Inc.’s comebackWall Street Watch & Long-Term Capital Growth Ideas - newser.com
Using data tools to time your Halozyme Therapeutics Inc. exitQuarterly Portfolio Report & Smart Money Movement Alerts - newser.com
Heatmap analysis for Halozyme Therapeutics Inc. and competitors2025 Support & Resistance & Fast Gain Swing Alerts - newser.com
Tectonic Advisors LLC Decreases Holdings in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) Upgraded by Weiss Ratings to "Buy (B-)" Rating - MarketBeat
Key metrics from Halozyme Therapeutics Inc.’s quarterly data2025 Top Decliners & Short-Term Swing Trade Alerts - newser.com
Halozyme Therapeutics Inc Stock Analysis and ForecastProtective Put Strategies & Budget Friendly Portfolio - earlytimes.in
Can Elektrofi Acquisition Drive Halozyme's Long-Term Growth? - Yahoo Finance
Halozyme Therapeutics (NASDAQ:HALO) Downgraded by Zacks Research to Hold - MarketBeat
Zacks Research Analysts Increase Earnings Estimates for HALO - MarketBeat
Halozyme Therapeutics (HALO): What Recent Gains Reveal About Its Current Valuation - Yahoo
Halozyme Therapeutics Experiences Evaluation Revision Amidst Mixed Market Signals - Markets Mojo
Halozyme Appoints New Chief Operating Officer - The Globe and Mail
Halozyme Therapeutics Names Cortney Caudill Chief Operating Officer - MarketScreener
Halozyme (HALO) Appoints New Chief Operating Officer - GuruFocus
Halozyme names Cortney Caudill as COO - TipRanks
Halozyme Therapeutics appoints Cortney Caudill as chief operating officer - Investing.com
Halozyme Therapeutics, Inc. Announces Appointment of Cortney Caudill as Senior Vice President and Chief Operating Officer, Effective October 1, 2025 - MarketScreener
Are Medical Stocks Lagging Armata Pharmaceuticals (ARMP) This Year? - Nasdaq
Pattern recognition hints at Halozyme Therapeutics Inc. upsideEarnings Overview Summary & Risk Managed Trade Strategies - newser.com
How buybacks impact Halozyme Therapeutics Inc. stock valueWeekly Trade Summary & Technical Pattern Based Signals - newser.com
How geopolitical risks impact Halozyme Therapeutics Inc. (RV7) stock2025 Support & Resistance & Capital Protection Trading Alerts - newser.com
Will Halozyme Therapeutics Inc. (RV7) stock outperform global peersWeekly Stock Analysis & AI Based Trade Execution Alerts - newser.com
33,600 Shares in Halozyme Therapeutics, Inc. $HALO Acquired by LGT Fund Management Co Ltd. - MarketBeat
111 Capital Makes New Investment in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) CEO Sells $1,380,600.00 in Stock - MarketBeat
Insider Selling: Halozyme Therapeutics (NASDAQ:HALO) CEO Sells 20,000 Shares of Stock - MarketBeat
Halozyme Announces Merger Agreement with Elektrofi - TipRanks
Halozyme Therapeutics says if deal is terminated under certain circumstances, co to pay Elektrofi reverse termination fee of $36 million - MarketScreener
Benchmark Sees More Upside for Halozyme Therapeutics (HALO), Hikes Price Target - MSN
Research Analysts Set Expectations for HALO FY2026 Earnings - MarketBeat
Institutional scanner results for Halozyme Therapeutics Inc.2025 Top Gainers & Daily Price Action Insights - newser.com
Is it too late to sell Halozyme Therapeutics Inc.Market Growth Summary & Free High Return Stock Watch Alerts - newser.com
Public Employees Retirement System of Ohio Acquires 38,049 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
Can volume confirm reversal in Halozyme Therapeutics Inc.July 2025 Gainers & Low Drawdown Investment Strategies - newser.com
Halozyme Therapeutics (NASDAQ:HALO) Shares Down 4.3% on Insider Selling - Defense World
What analysts say about Halozyme Therapeutics Inc RV7 stockStock Price Divergence & Small Investment Portfolio - earlytimes.in
Halozyme Acquires Elektrofi to Enhance Drug Delivery - MSN
Halozyme to acquire Elektrofi, a biopharma focused on drug delivery - MSN
Halozyme Therapeutics (NASDAQ:HALO) Trading Down 4.3% on Insider Selling - MarketBeat
HC Wainwright Increases Halozyme Therapeutics (NASDAQ:HALO) Price Target to $90.00 - MarketBeat
HC Wainwright & Co. Maintains Halozyme Therapeutics (HALO) Buy Recommendation - Nasdaq
Halozyme stock price target raised to $90 from $85 at H.C. Wainwright - Investing.com
Halozyme eyes microparticles in $900m Elektrofi acquisition - Yahoo Finance
AMI Asset Management Corp Sells 16,475 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
HC Wainwright & Co. Raises Price Target for Halozyme Therapeutics (HALO) | HALO Stock News - GuruFocus
H.C. Wainwright Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Raises Target Price to $90 - 富途牛牛
Bernadette Connaughton Sells 2,000 Shares of Halozyme Therapeutics (NASDAQ:HALO) Stock - MarketBeat
Insider Sell: Bernadette Connaughton Sells 2,000 Shares of Haloz - GuruFocus
Connaughton of Halozyme sells $150k in stock By Investing.com - Investing.com Australia
Halozyme Therapeutics Inc (HALO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Halozyme Therapeutics Inc 주식 (HALO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Torley Helen | PRESIDENT AND CEO |
Oct 01 '25 |
Option Exercise |
8.11 |
20,000 |
162,200 |
753,719 |
| Torley Helen | PRESIDENT AND CEO |
Oct 02 '25 |
Option Exercise |
8.11 |
20,000 |
162,200 |
753,719 |
| Torley Helen | PRESIDENT AND CEO |
Oct 01 '25 |
Sale |
75.35 |
20,000 |
1,507,024 |
733,719 |
| Torley Helen | PRESIDENT AND CEO |
Oct 02 '25 |
Sale |
71.20 |
20,000 |
1,424,083 |
733,719 |
| Torley Helen | PRESIDENT AND CEO |
Oct 03 '25 |
Sale |
69.03 |
20,000 |
1,380,638 |
733,719 |
| Connaughton Bernadette | Director |
Oct 01 '25 |
Sale |
75.24 |
2,000 |
150,481 |
44,952 |
5.74%
자본화:
|
볼륨(24시간):